Skip to content

Amended and Restated Compensation Committee Charter


The Compensation Committee of the Board of Directors (the “Compensation Committee”) of Esperion Therapeutics, Inc. (the “Company”), on behalf of the Board of Directors (the “Board”), discharges the Board’s responsibilities relating to compensation of the Company’s directors and executives, oversees the Company’s overall compensation structure, policies and programs, reviews the Company’s processes and procedures for the consideration and determination of director and executive compensation, and is responsible for producing a report for inclusion in the Company’s proxy statement relating to its annual meeting of stockholders or annual report on Form 10-K, in accordance with applicable rules and regulations.  The primary objective of the Compensation Committee is to develop and implement compensation policies and plans that ensure the attraction and retention of key management personnel, the motivation of management to achieve the Company’s corporate goals and strategies, and the alignment of the interests of management with the long-term interests of the Company’s stockholders.

The number of individuals serving on the Compensation Committee shall be fixed by the Board from time to time but shall consist of no fewer than three members, each of whom shall satisfy the independence standards established pursuant to Rule 5605(a)(2) of the NASDAQ Stock Market Rules, subject to any applicable exceptions contained in the NASDAQ Stock Market Rules.  In determining the members of the Compensation Committee, the Board will consider whether the members qualify as “non-employee directors” as defined in Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as “outside directors” as defined in Section 162(m) of the Internal Revenue Code of 1986, as amended.

The members of the Compensation Committee shall be appointed annually by the Board and may be replaced or removed by the Board at any time, with or without cause.  Resignation or removal of a Director from the Board, for whatever reason, shall automatically constitute resignation or removal, as applicable, from the Compensation Committee.  Vacancies occurring, for whatever reason, may be filled by the Board.  The Board shall designate one member of the Compensation Committee to serve as Chairperson of the Compensation Committee.

The Compensation Committee shall meet as often as it determines is appropriate to carry out its responsibilities, which meetings may be in person or by telephone conference or other communications equipment by means of which all persons participating in the meeting can hear each other.  A majority of the members of the Compensation Committee shall constitute a quorum for purposes of holding a meeting and the Compensation Committee may act by a vote of a majority of members present at such meeting.  In lieu of a meeting, the Compensation Committee may act by unanimous written consent in accordance with the Company’s bylaws. The Chairperson of the Compensation Committee, in consultation with the other members and management, may set meeting agendas consistent with this Charter.

The Compensation Committee’s purpose and responsibilities shall be to:

  1. Review of Charter
    • Review and reassess the adequacy of this Charter annually and submit any proposed changes to the Board for approval.
  2. Processes and Procedures for Considering and Determining Director and Executive Compensation
    • Review and reassess periodically (and where appropriate, make such recommendations to the Board as the Compensation Committee deems advisable with regard to) the Company’s processes and procedures for the consideration and determination of director and executive compensation, and review and discuss with management any description of such processes and procedures to be included in the Company’s proxy statement.
  3. Compensation Committee Report
    • Review and discuss with management the Compensation Discussion and Analysis, if required, to be included in the Company’s proxy statement or annual report on Form 10-K (“CD&A”).
    • Based on the Compensation Committee’s review and discussions with management of the CD&A, if required, make a recommendation to the Board that the CD&A be included in the Company’s proxy statement or annual report on Form 10-K.
    • Prepare the Compensation Committee Report to be included in the Company’s proxy statement or annual report on Form 10-K in accordance with the applicable rules and regulations of the Securities and Exchange Commission, any securities exchange on which the Company’s securities are traded, and any other rules and regulations applicable to the Company.
  4. Performance Evaluation of the Compensation Committee
    • Periodically perform a performance evaluation of the Compensation Committee and report to the Board on the results of such evaluation.
  5. Incentive-Compensation and Equity-Based Plans
    • Review and approve grants and awards under incentive-based compensation plans and equity-based plans, in each case consistent with the terms of such plans.
    • Review and make such recommendations to the Board as the Compensation Committee deems advisable with regard to policies and procedures for the grant of equity-based awards by the Company.
  6. Matters Related to Compensation of the Company’s Chief Executive Officer
    • Review and approve the corporate goals and objectives that may be relevant to the compensation of the Company’s Chief Executive Officer (“CEO”).
    • Evaluate the CEO’s performance in light of the goals and objectives that were set for the CEO and determine the CEO’s compensation based on such evaluation.  In connection with determining the long-term incentive component of the CEO’s compensation, the Compensation Committee should consider the Company’s performance and relative stockholder return, the value of similar incentive awards to CEOs at comparable companies, and the awards given to the Company’s CEO in past years.
    • The CEO may not be present during voting or deliberations concerning his or her compensation.
  7. Matters Related to Compensation of the Officers Other Than the Chief Executive Officer
    • Determine the compensation of all officers of the Company other than the CEO; for purposes hereof the term “officer” has the meaning defined in Section 16 of the Exchange Act and Rule 16a‑1 promulgated thereunder.

The Compensation Committee is authorized, on behalf of the Board, to do any of the following, as the Compensation Committee deems necessary or appropriate in its discretion:

  1. Matters Related to Compensation of the Company’s Directors and Members of Senior Management
    • Review and make such recommendations to the Board as the Compensation Committee deems advisable with regard to the compensation of the directors of the Company, including with respect to any equity-based plans, provided that the Board shall retain co-equal power in respect of all such delegated matters.
    • Determine the compensation of all members of senior management of the Company (other than the CEO and other officers described above), including with respect to any incentive-compensation plans and equity-based plans.
  2. Matters Related to Compensation Consulting Firms or Other Outside Advisors
    • Retain or obtain the advice of compensation consultants, legal counsel and/or other advisers; provided that:
    • The Compensation Committee is authorized to, and must, have direct responsibility for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel or other adviser retained by the Compensation Committee and the Company must provide for appropriate funding, as determined by the Compensation Committee, for payment of reasonable compensation to any such compensation consultant, legal counsel or other adviser; and 
    • Before any compensation consultant, legal counsel or other adviser (other than (1) in-house legal counsel or (2) any compensation consultant, legal counsel or other adviser whose role is limited to the following activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K: (i) consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of executive officers or directors of the Company, and that is available generally to all salaried employees or (ii) providing information that either is not customized for a particular company or that is customized based on parameters that are not developed by the compensation consultant, legal counsel or other adviser and about which the compensation consultant, legal counsel or other adviser does not provide advice) is selected by, or provides advice to, the Compensation Committee, the Compensation Committee shall take into consideration the following factors:
    • The provision of other services to the Company by the person that employs the compensation consultant, legal counsel or other adviser;
    • The amount of fees received from the Company by the person that employs the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the person that employs the compensation consultant, legal counsel or other adviser;
    • The policies and procedures of the person that employs the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest;
    • Any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Compensation Committee;
    • Any stock of the Company owned by the compensation consultant, legal counsel or other adviser; and
    • Any business or personal relationship of the compensation consultant, legal counsel, other adviser or the person employing the adviser with an executive officer of the Company.
    • Prohibit the Company from engaging a compensation consultant engaged by the Compensation Committee, or an affiliate of any such compensation consultant, to provide any other services to the Company without the approval of the Compensation Committee.
  • The Compensation Committee may establish and delegate authority to one or more subcommittees consisting of one or more of its members, when the Compensation Committee deems it appropriate to do so in order to carry out its responsibilities.
  • The Compensation Committee shall make regular reports to the Board concerning areas of the Compensation Committee’s responsibility.
  • In carrying out its responsibilities, the Compensation Committee shall be entitled to rely upon advice and information that it receives in its discussions and communications with management and such experts, advisors and professionals with whom the Compensation Committee may consult.  The Compensation Committee shall have the authority to request that any officer or employee of the Company, the Company’s outside legal counsel, the Company’s independent auditor or any other professional retained by the Company to render advice to the Company attend a meeting of the Compensation Committee or meet with any members of or advisors to the Compensation Committee. 
  • The Compensation Committee may perform such other functions as may be requested by the Board from time to time.

Adopted June 5, 2013, subject to effectiveness of the Company’s Registration Statement on Form S-1.


Committee Members

Nicole Vitullo
Director, Domain Associates, LLC

Nicole Vitullo has served as a member of our board of directors since April 2008. Nicole joined Domain Associates, LLC, a venture capital firm with an exclusive focus on life sciences, in 1999, and became a Partner in 2004. From 1992-1999, Nicole was Senior Vice President at Rothschild Asset Management, Inc. Nicole is a director of a number of companies including Celator Pharmaceuticals, Inc.(NASDAQ: CPXX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Durata Therapeutics, Inc. (NASDAQ: DRTX), Marinus Pharmaceuticals, Inc. and VentiRx Pharmaceuticals, Inc. Nicole earned a B.A. and an M.B.A from the University of Rochester.

Antonio Gotto, Jr., MD, DPhil
Dean Emeritus & Co-Chair of Board of Overseers, Weill Cornell Medical College

Antonio M. Gotto, Jr. was appointed to our board of directors in January 2014. Antonio is Co-Chairman of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University and Vice President of Cornell University. From January 1997 to December 2011, he served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University. Previously, Antonio served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital. Antonio currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. He is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. Antonio holds a BA degree from Vanderbilt University, a DPhil degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an MD degree from Vanderbilt University School of Medicine. Antonio completed his residency training at Massachusetts General Hospital in Boston, Massachusetts. He is also a member of the Board of Directors of Aegerion Pharmaceuticals, Inc.

Dan Janney
Managing Director, Alta Partners

Dan Janney has served as a member of our board of directors since November 2012. Dan is a managing director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, Dan was a Vice President in Montgomery Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. He is a director of a number of companies including Alba Therapeutics Corporation, DiscoveRx Corporation, Lithera, Inc., Prolacta Bioscience, Inc. and ViroBay, Inc. Dan earned a BA of Arts in History from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles.

 

Gilbert S. Omenn, MD, PhD
Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, University of Michigan

Gilbert S. Omenn, MD, PhD, was appointed to our board of directors in June 2014.  Gil is Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, and Director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. He serves on the Scientific Management Review Board of the National Institute of Health (NIH) and the Community Preventive Services Task Force of the Centers for Disease Control and Prevention (CDC). Previously, Gil served as Chief Executive Officer of the University of Michigan Health System and Executive Vice President of the University of Michigan for Medical Affairs. He was Professor of Medicine and of Environmental Health, and Dean of the School of Public Health and Community Medicine, at the University of Washington. Gil was a member of the intramural program of NIH in the Anfinsen Lab and was a Howard Hughes Investigator with NIH grants spanning four decades. He served previously on the National Cancer Advisory Board, NIH Heart, Lung and Blood Institute Advisory Council, Society of Fellows for the NIH National Center for Minority Health and Health Disparities and on the Director’s Advisory Committee for the CDC. Gil earned his Bachelor’s degree summa cum laude from Princeton University, his medical degree magna cum laude from Harvard Medical School, and his PhD in genetics from the University of Washington. Previously, Gil has been a member of the board of directors for Amgen Inc. and Rohm & Haas Company.